Table 1.
Baseline features.
|
Literature review and CHUM cohort(63 W, 80 P) |
CHUM cohort only(10 W, 12 P) |
|||
|---|---|---|---|---|
| N | Median (range) | N | Median (range) | |
| Age (y) | 63 | 29 (17–41) | 12 | 31.5 (18–41) |
| Disease duration (y) | 61 | 5 (0–13) | 11 | 7 (0–13) |
|
P/N |
% |
P/N |
% |
|
| Primiparous | 20/53 | 37.7 | 7/12 | 58.3 |
| Good disease controla | 21/26 | 80.8 | 9/10 | 90.0 |
| Steroids/Immunosupp.b | 15/35 | 42.9 | 3/10 | 30.0 |
| Active diseasec | 26/70 | 37.1 | 1/12 | 8.8 |
| ANA | 46/47 | 97.9 | 11/12 | 91.7 |
| Anti-Ro | 14/44 | 31.8 | 5/10 | 50.0 |
| Anti-La | 6/36 | 16.7 | 3/10 | 30.0 |
| Anti-Smith | 9/22 | 40.9 | 5/10 | 50.0 |
| Anti-dsDNA | 5/19 | 26.3 | 4/9 | 44.4 |
| Low complement | 4/16 | 25.0 | 1/9 | 11.1 |
N: available sample size per category; P: pregnancy; W: women.
aGood control of mixed connective tissue disease six months prior to pregnancy.
bSteroids or immunosuppressive drugs.
cIncluding relapses in pregnancy and de novo diagnosis up to six weeks PP.